Pediatric Rare Disease Voucher Program Faces Expiration
Stakeholders push Congress to renew program, although 21st Century Cures route unlikely.
You may also be interested in...
Next fiscal year will be a good one to redeem a voucher, and probably to qualify for one as well.
It sparked at least one analyst to question how Sarepta came up with a price for FDA's first approved Duchenne muscular dystrophy treatment.
Generics industry and FDA have resolved remaining issues regarding financing of user fee program.